Navigation Links
Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
Date:12/3/2009

WALTHAM, Mass., Dec. 3 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (NYSE: IMA), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management, has declared a dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock ( IMA-PB). The dividend will be paid in shares of Series B stock in an amount per share equal to the quotient of (a) $3.00 divided by (b) 97% of the average of the volume-weighted average price per share of the Series B stock on the New York Stock Exchange for each of the five consecutive trading days ending on the second trading day immediately prior to the record date of the dividend. Inverness will pay cash in lieu of any fractional shares resulting from the dividend. The dividend is payable on January 15, 2010 to holders of record of Series B stock at the close of business on January 4, 2010.

Such payment will cover the amount of all dividends accrued from October 1, 2009 through December 31, 2009.

For more information about Inverness Medical Innovations, please visit our website at http://www.invernessmedical.com.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life. Inverness' global leading products and services, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

SOURCE Inverness Medical Innovations, Inc.


'/>"/>
SOURCE Inverness Medical Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 27, 2009 to Discuss Third Quarter 2009 Results
2. Inverness Medical Innovations - Concateno plc, Further Announcement Regarding UK Takeover Code Share Dealing Disclosure Requirements.
3. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
4. Inverness Medical Innovations Announces Third Quarter 2008 Results
5. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET October 29, 2008 to Discuss Third Quarter 2008 Results
6. Inverness Medical Innovations to Present at the UBS Global Life Sciences Conference on September 22, 2008
7. Inverness Medical Innovations to Attend the Goldman Sachs Diagnostics Conference on September 18, 2008
8. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
9. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
10. Inverness Medical Innovations Features Innovative TB Diagnostic - Clearview(R) TB ELISA at AIDS 2008
11. Inverness Medical Innovations to Present at Canaccord Adams 28th Annual Growth Conference on August 12, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... BEACH, Fla. , July 11, 2014 /PRNewswire-iReach/ -- ... of high-quality peptides that are used solely in scientific ... honor two successful years in business, Maxim Peptide, which ... has just launched a new and updated website that ... research blog section has been updated with fascinating articles ...
(Date:7/11/2014)... -- EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is to ... The new Wyss Center for Bio- and ... , has named as its director one of ... , founder of Brown University,s Institute for Brain Science, ...
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... 17 , - MedITEX IVF Facilitates ... - MedITEX from 28 June to 1 ... The IT consulting company CRITEX, which specialises in ... fertilisation, MedITEX IVF,at the 25th Annual Meeting of the European Society ...
... , FREMONT, Calif., June 16 Microfluidic Systems, ... patent number 7,541,166, entitled "Sonication to Selectively Lyse ... the process of differential extraction of male/female DNA ... in a wide variety of biological sample processes ...
... and Webcast on Wednesday, June 17 at 8:30 a.m. Eastern ... Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced ... Food and Drug Administration (FDA) recommended by a vote of ... PEGylated uricase enzyme, be granted marketing approval by the FDA ...
Cached Biology Technology:New IVF Software MedITEX to be Presented at the ESHRE Exhibition 2MicroFluidic Systems (MFSI) Receives Patent for Method to Selectively Process Different Biological Cell Types for Analysis. 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 2FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 3FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for KRYSTEXXA(TM) for Refractory Chronic Gout 4
(Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
(Date:7/10/2014)... , July 2, 2014 NXT-ID, Inc., (OTCQB: NXTD) a biometric ... CEO Mr. Gino Pereira was interviewed on July ... Tampa Florida . Mr. Pereira discusses the ... Cedric Harris and how the Wocket™ aims to replace ... Cedric Harris tells Gino he has ...
(Date:7/10/2014)... Fingerprint Cards, (FPC,s) new mobile touch ... Asian OEM has selected FPC1021 for a flagship model with ...   FPC is proud to announce this DW ... for start of mass production in August 2014. FPC has ... delivery in the first half of July. The OEM wants ...
Breaking Biology News(10 mins):SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4FPC Wins DW and Initial Ramp Order for FPC1021 Touch Sensor for Flagship Smartphone from Asian OEM 2
... to developing new antibiotics, and a technique called solid-state ... , That's the view of University of Michigan ... toward that goal March 3 at the annual meeting ... Ramamoorthy's research group is using solid-state NMR to explore ...
... Flavonoids, a group of compounds found in fruits and ... for their antioxidant activity, actually have little or no ... scientists in the Linus Pauling Institute at Oregon State ... human health, but for reasons that are quite different ...
... of the persistent riddles of the deadly 1918 Spanish ... varying severity. Why were some municipalities such as St. ... Philadelphia when both implemented similar public health measures? What ... by the National Institutes of Health (NIH), was not ...
Cached Biology News:Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3Studies force new view on biology of flavonoids 2Studies force new view on biology of flavonoids 3Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4
Smac/DIABLO (CT) - IgG for Western Blotting, Host: Rabbit Family: Smac/DIABLO...
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
Biology Products: